Form 8-K - Current report:
SEC Accession No. 0001213900-25-066819
Filing Date
2025-07-23
Accepted
2025-07-23 08:36:03
Documents
13
Period of Report
2025-07-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248817-8k_oramed.htm   iXBRL 8-K 33222
2 OPTION AGREEMENT FOR REPURCHASE OF WARRANTS, DATED JULY 22, 2025, BETWEEN SCILEX ea024881701ex10-1_oramed.htm EX-10.1 117862
  Complete submission text file 0001213900-25-066819.txt   346516

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ormp-20250722.xsd EX-101.SCH 3008
4 XBRL LABEL FILE ormp-20250722_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE ormp-20250722_pre.xml EX-101.PRE 22354
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248817-8k_oramed_htm.xml XML 3688
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 251141694
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)